1. Why have the authors excluded CINAHL and Cochrane database from their list of databases to be searched. 2. What strategy will be used to identify online African journals. 3. Will the authors attempt to identify conference abstracts, especially the World Congress of Nephrology and the AFRAN Congresses? 4. Duration : clarify "from inception" 5. In the criteria for studies that will not be included, how do the authors plan to resolve the following situations -The diagnosis of CKD that might have been silent before may be made in a patient who presents with a sentinel CVD event -clarify what are "key and computable data" 6. They plan to do regional analyses -how do they plan to deal with heterogeneity in multiple studies from the same country/region 7. Since one expects most CVD diagnosis to be made in urban hospitals, how will the authors identify urban/rural origins of the population and how will the diagnosis be made in community based setting. 8. What will be the criteria for identification of CVD -self reported/investigations?
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GENERAL COMMENTS REVIEWER"S COMMENTS
It is an interesting protocol for a systematic review and metaanalysis to assess the prevalence, incidence and mortality attributable to CVD in chronic kidney disease patients. The introduction is also well-written outlining the gaps in knowledge and the need to do such a review for the African continent. However, I have a few comments in this regard.
The authors should describe the outcomes clearly i.e. incidence definitions (as mentioned below) and sub-groups of CVD mortality considered. Also, the statistical terms/methods need a bit more clarity and organization (also see below).
In the Abstract, the authors should emphasize on I2 as well for heterogeneity because the Chi-square and resulting P-value based tests can be influenced by power that is determined by the number of studies in the meta-analysis.
The authors use the word "incidence". However, incidence is of two types: one is cumulative incidence (risk, incidence proportion) in which the denominator is total subjects at risk and the other is incidence rate i.e. in which the denominator is in terms of personyears at risk. The authors should use both these incidences and explain each of them clearly a priori in the protocol.
It is not clear what do authors mean by "pattern of CVD" in CKD patients. It is a very non-specific term.
When the authors mention mortality rate (that I assume will be risk or a incidence proportion), then how do authors plan to adjust for the different duration of follow-up in different studies?
In the search strategy, use of words like coronary heart disease should be put in quotations like "coronary heart disease" [tw] so that all three words are taken together as a single phrase when the MEDLINE searches for the text term.
The authors should specify why they are using random effects metaanalysis as the preferred model type a priori rather than fixed effects meta-analysis.
The authors talk about Cohen"s ĸ coefficient but it will measure what degree of agreement? Is it inter-rater reliability as per the reference?
May be because the authors mention multiple variables for subgroup analyses, it might be useful to do a meta-regression first and then sub-group analyses for significant variables.
Page 8, Line 46 -47: The word "identical" should be replaced with word "similar".
I am not clear what is "The Freeman-Tukey double arc-sine transformation" that the authors state will be used to stabilize variance of individual studies. I am not familiar with this transformation and if the authors can explain its utility in more detail rather than just to say to stabilize the variances of individual studies. What advantages will it have in addition to the pooled point estimate and variance from meta-analysis?
The authors should also add a paragraph on the strengths and limitations of their protocol in the Discussion.
REVIEWER
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GENERAL COMMENTS
Prevalence and pattern of cardiovascular disease in African patients with CKD
General Comment: There is a growing body of work both within sub-Saharan Africa, and among African populations living outside of the region, which points to the substantial health burden of CKD and of its risk factorscommunicable and non-communicable diseases. As such, this paper has the potential to make a useful contribution to this knowledgebase, if some of the limitations, described below, are taken into consideration by the authors to improve this manuscript.
One of the more recent publications on the topic, by Stanifer et al, 2014 on the epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis, not refered to in this paper (http://dx.doi.org/10.1016/ S2214-109X(14)70002-6), highlights two problems, a) the small number of studies overall, and b) the limit of the available information-poor quality of data and as a result, the limitations in the inferences that can be drawn from them.
This points to a major challenge in undertaking the proposed review, the small number of studies focusing on the CKD and including Cardiovascular disease as an outcome in African patients. For example, according to Stanifer and others, after reviewing more than 900 studies, with much broader search parameters than propose in this review, they identified less than 10 studies of medium-high quality that combined CKD with diabetes and hypertension. It is not clear whether the authors have undertaken any exploratory literature review to determine the feasibility of the proposed systematic review in terms of the breadth and depth of the available data. As the literature cited in the background is limited, it is difficult for a reviewer to make this assessment and to comment on the usefulness for this review and/or its potential for improving our understanding of cardiovascular disease in African patients with CKD.
More specific feedback:
Abstract-needs revision in light of the above note and the comments below. Ethics and dissemination section: the information is redundant, given the nature of the paper, these concerns are explicit to the reader.
Strengths and limitations: Although the authors state that the small number of studies is a limitation and propose to include all cardiovascular diseases to address this concern, this does not align with the research questions -what is the prevalence of cardiovascular mortality and morbidity in patients with CKD? The focus is on first finding studies focusing on CKD, and also because the authors plan to exclude studies which has CKD as an outcome of cardiovascular disease.
Introduction -needs revision in light of the above general comment.
Search terms: The aim is to show link between cardiovascular diseases as an outcome of CKD. However in the manner it is presented, there appears to be a focus on the cardiovascular disease component rather than the CKD aspect of the link, it is assumed that you would start with a either a specific definition of CKD, or a broad search which includes conditions labelled as "chronic" AND "renal impairment", "end/target-renal damage", "endstage kidney/renal disease", "nephropathy", "proteinuria", "dialysisdependent", etc., and then ADD MESH terms for cardiovascular disease. Please clarify.
The time parameter is not clear, will the authors include studies from before 1980, example, and if so what relevance would this have for the knowledge being synthesized here?
Reporting guidelines: In different places of the manuscript the authors refer to MOOSE and PRIMA guidelines, it is not clear which one is being used.
Analysis: the analysis is a general overview and not described in enough details for the review to be replicated. The analysis is described in most reporting guidelines, and without details of how you would apply to this data, i.e. to account for various definitions and parameters used in reporting prevalence in mortality, for example, across studies, from different time periods.
Conclusions: It is not clear how this review will directly contribute to the stated conclusion -"will help reduce the burden of CKD in Africa." Also they mentioned the paucity of studies, which will also not be addressed in this context, however, the authors will be able to, based on their findings, draw attention to and call for empirical studied to address the knowledge gaps, if any, that they highlight after completing the review. This section needs revision to better align with the research question and methods.
VERSION 1 -AUTHOR RESPONSE

Reviewer1:
Reviewer"s comment 1: The Authors should clarify which kind of data they expect to retrieve from the literature in terms of number of studies / patients and summarize in the Introduction the results of the main studies, if any.
Authors" response 1: Many thanks for the suggestion we have added the keys data which we expect to retrieve from the literature at the end of the "Introduction" section.
Reviewer"s comment 2: The Authors should also clarify why excluding "studies which show evidence of CVD as cause of CKD or CVD which exist before diagnosis of CKD", as in many cases it is unclear which came first in the context of the cardiorenal syndromes.
Authors" response 2: Thank you for such a pertinent comment. Indeed, in most cases, it is difficult to depict which event came first, especially in non-cohort studies. This has been removed as exclusion criteria.
Reviewer 2: Reviewer"s comment 1: Why have the authors excluded CINAHL and Cochrane database from their list of databases to be searched?
Authors" response1: Thank you very much; we did not include Cochrane database because it deal most with "Interventional studies" than "Observational studies". Like you have suggested we have added CINAHL and another broad database known as WHO Global Health Library databases.
Reviewer"s comment 2: What strategy will be used to identify online African journals?
Authors" response 2: Thank you, AFRO which is a part of WHO Global Health Library databases contain specifically online African journals
Reviewer"s comment 3: Will the authors attempt to identify conference abstracts, especially the World Congress of Nephrology and the AFRAN Congresses?
Authors" response 3: Thank you for your pertinent question. We shall search and include all eligible conference abstracts including those from the World Congress of Nephrology and the AFRAN Congresses. This has been included in 10th line of the "bibliographic database searches" section of the main text. This section now reads, "Finally, we shall search relevant conference papers from the World Congress of Nephrology and the African Nephrology congresses."
Reviewer"s comment 4: Duration: clarify "from inception"
Authors" response 4: Thank you, we have modified the "Duration" and this sentence can now be read as: "We will consider all published or unpublished data from 1st May 1987 to 1st May 2017"
Reviewer"s comment 5: In the criteria for studies that will not be included, how do the authors plan to resolve the following situations: The diagnosis of CKD that might have been silent before may be made in a patient who presents with a sentinel CVD event.
Authors" response 5: Thank you for this crucial question. This issue was raised by reviewer no.1. To determine the prevalence of CVD in CKD, we will consider all cases of CVD in CKD patients, independent of the event which occurred first; as it will be impossible to depict this detail from these studies. But to estimate the incidence risk, we will consider only cohort studies which will focus on the occurrence of new CVD event in CKD patients.
Reviewer"s comment 6: clarify what are "key and computable data"
Authors" response 6: Thank you for your comment. By key and computable data, we meant sufficient data to determine the prevalence, incidence and mortality risk of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). We have clarified this in the main text. This section of the text now reads, "Studies lacking data to compute the prevalence, incidence or mortality of CVD in patients with CKD."
Reviewer"s comment 7: They plan to do regional analyses -how do they plan to deal with heterogeneity in multiple studies from the same country/region
Authors" response 7: Thank you for the pertinent question. In case of heterogeneity of multiple studies from the same country/region, we will perform a subgroup analysis to detect its possible sources, as stated in line 6 of the "Data synthesis and analysis" paragraph
Reviewer"s comment 8: Since one expects most CVD diagnosis to be made in urban hospitals, how will the authors identify urban/rural origins of the population and how will the diagnosis be made in community-based setting.
Authors" response 8: Thank you for your question. Even though a lot of the diagnostic tools exist for the diagnosis of CVD, basic diagnostic tools like the electrocardiogram and a 2D echocardiogram are usually available in these settings, and we intend to rely on them.
Reviewer"s comment 9: What will be the criteria for identification of CVD -selfreported/investigations?
Authors" response 9: Thank you for such an important question. We shall recommend investigations as a criterion for identifying CVDs and CKDs alike. The use of self-reporting as a criterion for identifying either CVDs or CKDs has been included as an exclusion criterion.
Reviewer 3:
Reviewer"s comment 1: The authors should describe the outcomes clearly i.e. incidence definitions (as mentioned below) and sub-groups of CVD mortality considered. Also, the statistical terms/methods need a bit more clarity and organization (also see below).
Authors" response 1: Many thanks, we have addressed this pertinent comments below Reviewer"s comment 2: In the Abstract, the authors should emphasize on I2 as well for heterogeneity because the Chi-square and resulting P-value based tests can be influenced by the power that is determined by the number of studies in the meta-analysis.
Authors" response 2: Thank you for your suggestion. This sentence has been modified and now reads:"Clinically homogenous studies will be pooled after assessing for clinical and statistical heterogeneity using the χ2 test on Cochrane"s Q statistic which is quantified by I2 values, assuming that I2 values of 25%, 50% and 75%,respectively, represent low, medium and high heterogeneity"
Reviewer"s comment 3: The authors use the word "incidence". However, the incidence is of two types: one is cumulative incidence (risk, incidence proportion) in which the denominator is total subjects at risk and the other is incidence rate i.e. in which the denominator is in terms of person-years at risk. The authors should use both these incidences and explain each of them clearly a priori in the protocol.
Authors" response 3: Thank you for this pertinent comment. We have modified the second question under the "review question" section, and can now be read as follows: "What are the cumulative incidence and the incidence rate of CVD in patients with CKD in LMICs?"
Reviewer"s comment 4: It is not clear what do authors mean by "pattern of CVD" in CKD patients. It is a very non-specific term
Authors" response 4: Thank you for your comment. We have modified the title without the word "pattern". The title can now be read as follows: "Prevalence, incidence and associated mortality of cardiovascular diseases in patients with chronic kidney disease in Low and Middle-Income countries: a protocol for a systematic review and meta-analysis" Reviewer"s comment 5: When the authors mention mortality rate (that I assume will be risk or a incidence proportion), then how do authors plan to adjust for the different duration of follow-up in different studies?
Authors" response 5: Thank you for your suggestion. The term "mortality rate" has been replaced by "mortality risk" through the text.
Reviewer"s comment 6: In the search strategy, use of words like coronary heart disease should be put in quotations like "coronary heart disease" [tw] so that all three words are taken together as a single phrase when the MEDLINE searches for the text term.
Authors" response 6: Thank you for the remark. All corrections have been done accordingly.
Reviewer"s comment 7: The authors should specify why they are using random effects meta-analysis as the preferred model type a priori rather than fixed effects meta-analysis.
Authors" response 7: Thank you for this pertinent question. Under the fixed effect model, we assume that there is one true effect size which is shared by included studies. In contrast, we based on the assumption that the true effect could vary from study to study in the random effect model; and we are trying to estimate the mean of a distribution of true effects. Therefore, the weights assigned under random effects are more balanced. Large studies, for example, are less likely to dominate the analysis and small studies are less likely to be trivialized.
Reviewer"s comment 8: The authors talk about Cohen"s ĸ coefficient but it will measure what degree of agreement? Is it inter-rater reliability as per the reference?
Authors" response 8: Thank you for your question. The Cohen"s κ coefficient will be used to assess the Inter-rater agreement for study inclusion
Reviewer"s comment9: May be because the authors mention multiple variables for sub-group analyses, it might be useful to do a meta-regression first and then sub-group analyses for significant variables.
Authors" response 9: Thank you for your suggestion. We do agree with the reviewer. We will conduct meta-regression analysis as one can read: "Where substantial heterogeneity will be detected, we will perform a subgroup analysis and meta-regression to detect its possible sources using the following grouping variables: age groups, sex, study setting (rural vs urban; hospital vs community-based), country and geographical region (Africa, Americas, Eastern Mediterranean, Europe, South-East Asia, and Western Pacific), type of CVD, stage of CKD, and study quality."
Reviewer"s comment 10: Page 8, Line 46 -47: The word "identical" should be replaced with word "similar".
Authors" response 10: Thank you for the suggestion, the word "identical" has been replaced with "similar"
Reviewer"s comment 11: I am not clear what is "The Freeman-Tukey double arc-sine transformation" that the authors state will be used to stabilize variance of individual studies. I am not familiar with this transformation and if the authors can explain its utility in more detail rather than just to say to stabilize the variances of individual studies. What advantages will it have in addition to the pooled point estimate and variance from meta-analysis?
Authors" response 11: Thank you for this comment. Freeman-Tukey transformation seeks to adjust data making the distribution more similar to a normal distribution and therefore improve the accuracy of the pooled estimates. The Freeman-Tukey double arc-sine transform is used for binomial-like data as it is the case for our data.
We don"t feel it is important to explain in the Data synthesis and analysis sub-section what the Freeman-Tukey double arc-sine transformation is, because it is a technique very commonly used in the meta-analysis, and such explanations will inappropriately increase the length of the manuscript.
Reviewer"s comment 12: The authors should also add a paragraph on the strengths and limitations of their protocol in the Discussion.
Authors" response 12: Thank you for the suggestion. A paragraph on the strengths and limitations has been added in the conclusion section.
Reviewer 4:
Reviewer"s comment1: General Comment: There is a growing body of work both within sub-Saharan Africa, and among African populations living outside of the region, which points to the substantial health burden of CKD and of its risk factorscommunicable and non-communicable diseases. As such, this paper has the potential to make a useful contribution to this knowledge-base, if some of the limitations, described below, are taken into consideration by the authors to improve this manuscript.
This points to a major challenge in undertaking the proposed review, the small number of studies focusing on the CKD and including cardiovascular disease as an outcome in African patients. For example, according to Stanifer and others, after reviewing more than 900 studies, with much broader search parameters than propose in this review, they identified less than 10 studies of medium-high quality that combined CKD with diabetes and hypertension. It is not clear whether the authors have undertaken any exploratory literature review to determine the feasibility of the proposed systematic review in terms of the breadth and depth of the available data.
As the literature cited in the background is limited, it is difficult for a reviewer to make this assessment and to comment on the usefulness for this review and/or its potential for improving our understanding of cardiovascular disease in African patients with CKD.
Authors" response 1: Thank you for your pertinent comment. We ran an initial search in relation to your query and indeed the number of eligible studies was grossly insufficient. Consequently, we widened the scope of our study to include low-and middle-Income Countries, as these countries share a similar burden of CKD. We have adjusted out title and search strategies accordingly
Reviewer"s comment2: Abstract-needs revision in light of the above note and the comments below. Ethics and dissemination section: the information is redundant, given the nature of the paper, these concerns are explicit to the reader.
Authors" response 2: Thank you for your comment. The abstract has been modified and also the Ethics and dissemination section. These can now be read as follow: "This proposed study will not require ethical approval since it will be based on published data."
Reviewer"s comment 3: Strengths and limitations: Although the authors state that the small number of studies is a limitation and propose to include all cardiovascular diseases to address this concern, this does not align with the research questions -what is the prevalence of cardiovascular mortality and morbidity in patients with CKD? The focus is on first finding studies focusing on CKD, and also because the authors plan to exclude studies which has CKD as an outcome of cardiovascular disease.
Authors" response 3: Many thanks for your comments. We will focus now in Low-and Middle-income countries not only in Africa, this will permit us to have more studies and to address the research questions. However, we have adjusted our search strategy to include all papers on patients with CKD first, before identifying those reporting on CVD. We have presented broad terms for CKD before adding MESH terms for cardiovascular diseases.
Reviewer"s comment4: Introduction -needs revision in light of the above general comment Authors" response 4: Thank you for your comment. Revisions have been done accordingly.
Reviewer"s comment5: Search terms: The aim is to show link between cardiovascular diseases as an outcome of CKD. However in the manner it is presented, there appears to be a focus on the cardiovascular disease component rather than the CKD aspect of the link, it is assumed that you would start with a either a specific definition of CKD, or a broad search which includes conditions labelled as "chronic" AND "renal impairment", "end/target-renal damage", "end-stage kidney/renal disease", "nephropathy", "proteinuria", "dialysis-dependent", etc., and then ADD MESH terms for cardiovascular disease. Please clarify.
Authors" response 5: Thank you for the suggestion. The search strategy has been adjusted our search strategy to include all papers on patients with CKD first, before identifying those reporting on CVD. We have presented broad terms for CKD before adding MESH terms for cardiovascular diseases.
